Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer’s.
Can a Drug Prevent Alzheimer’s Disease Decades Before It Happens? (Links to an external site)
Category: News
International Alzheimer’s prevention trial in young adults begins (Links to an external site)
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise
New drug targets for Alzheimer’s identified from cerebrospinal fluid (Links to an external site)
Study pegs certain cellular activities to driving Alzheimer’s disease. Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and progression.
A Country Doctor, But Oh So Much More: Francisco Lopera, 73 (Links to an external site)
The DIAN and DIAN-TU are deeply saddened by the recent death of our beloved colleague, Dr. Francisco Lopera, Principal Investigator at our site in Colombia (Grupo Neurociencias de Antioquia – GNA). Alzforum offers this remembrance, highlighting the impact of Dr. Lopera’s work on the AD field.
First Success Stories From Alzheimer’s Secondary Prevention Trial (Links to an external site)
As discussed at the Alzheimer’s Association International Conference in Philadelphia, nearly two dozen mutation carriers who took gantenerumab for eight years had half the risk of developing symptoms as did untreated controls.
Living Among Us: People Whose Alzheimer’s Is Already Being Prevented (Links to an external site)
Many researchers think the full promise of plaque removal lies in prevention. If plaques were abolished before they could kick off downstream pathologies such as tangles, would the disease be stopped in its tracks?
The Knight Family DIAN-TU-003 Amyloid Removal Trial
DIAN-TU is launching the DIAN-TU-003 Amyloid Removal Trial (ART) to enable continued treatment for the DIAN-TU-001 Gantenerumab Open Label Extension (OLE) participants and address questions regarding the effects of removing amyloid plaques to normal levels on cognitive symptoms, clinical progression and disease processes.
The Knight Family DIAN-TU Primary Prevention Trial
We are now pleased to announce plans to re-launch the DIAN-TU-002 Primary Prevention Trial with remternetug in collaboration with Eli Lilly and Company (Lilly).
The New Age of Alzheimer’s (Links to an external site)
The soaring burden of dementia threatens global health. Science is paving new paths to solutions.
Moment of promise (Links to an external site)
WashU School of Medicine recently dedicated the new 609,000-square-foot Jeffrey T. Fort Neuroscience Research Building, which houses some 120 research teams — one of the highest concentrations of neuroscientists in the world.